<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04028700</url>
  </required_header>
  <id_info>
    <org_study_id>PRO00035124</org_study_id>
    <nct_id>NCT04028700</nct_id>
  </id_info>
  <brief_title>The Impact of Oxidative Stress on Erythrocyte Bilogy</brief_title>
  <acronym>RBC Survival</acronym>
  <official_title>Red Blood Cell Survival Study: The Impact of Oxidative Stress on Erythrocyte Bilogy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Versiti</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Versiti</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will address if red blood cells transfused to a sickle cell patient from a donor
      with a G6DP enzyme deficiency have a different lifespan as measured by the percentage of red
      blood cells that survive post-transfusion compared to red blood cells transfused to a sickle
      cell patient from a donor without a G6DP enzyme deficiency.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective, phase II, crossover, single-blind, randomized transfusion order study will
      address if red blood cells from donors with a G6DP enzyme deficiency have a different
      lifespan once transfused into a patient with sickle cell disease than red blood cells from an
      otherwise normal donor. Results of this critical study will guide future research and donor
      testing policies to ensure that patients receive the most appropriate units of blood for
      their condition. Each patient randomized to the study will receive 2 blood transfusions, one
      from a G6DP deficient donor and one from an otherwise normal donor. Half the patients (8)
      will receive G6DP deficient blood first while the other half (8) will receive non-G6DP
      deficient blood first. Patients will have a wash-out period of at least 3 months before
      receiving the opposite type of blood transfusion. The blood transfusion order will be
      randomized. There is currently no standard of testing in place to screen blood donations for
      G6DP enzyme deficiency. It is believed that up to 10% of the antigen-matched donors for
      patients with sickle cell disease are G6DP deficient, and the lifespan is unknown in the
      sickle cell population.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Patients will not be told which type of blood they are receiving first. There is no way to tell if blood has enzyme deficiencies by looking at it.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Post-Transfusion Recovery</measure>
    <time_frame>24 hours</time_frame>
    <description>Percentage of Red Blood Cells surviving post-transfusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin A</measure>
    <time_frame>4 weeks post-transfusion</time_frame>
    <description>Change in hemoglobin A from pre-transfusion to 4 weeks post-transfusion</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Sickle Cell Disease Without Crisis</condition>
  <arm_group>
    <arm_group_label>G6DP Deficient Red Blood Cell Transfusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transfusion of red blood cells that have been identified by local laboratory procedures to be deficient in G6PD enzyme activity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-G6DP deficient Red Blood Cell Transfusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transfusion of red blood cells that have been identified by local laboratory procedures to not be deficient in G6DP enzyme activity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Red Blood Cell Transfusion</intervention_name>
    <description>Patients will receive a red blood cell transfusion. The last 50mL of the transfusion will be labeled with chromium to allow investigators to study the lifespan of the red blood cells transfused into each patient.</description>
    <arm_group_label>G6DP Deficient Red Blood Cell Transfusion</arm_group_label>
    <arm_group_label>Non-G6DP deficient Red Blood Cell Transfusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-60 years

          2. HbSS/HbSβ0-thalassemia

          3. Stead state (no pain or baseline pain and ≥1 month from any hospital admission)

          4. Received ≥1 RBC transfusion in the past 2 years, but none in the past 120 days.

        Exclusion Criteria:

          1. Currently on a chronic transfusion program

          2. History of transfusion reactions not adequately managed by antihistamines

          3. ≥2 alloantibodies or warm autoantibodies

          4. Known G6PD deficiency

          5. Known iron overload (ferritin &gt;2000)

          6. Hepato- or splenomegaly

          7. Participation in another therapeutic trial

          8. Pregnant or nursing

          9. HIV positive

         10. At investigator discretion for uncontrolled inter-current illness or social situation
             limiting compliance with study requirements.

         11. Inability to speak and/or read English
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Matt Karafin, MD, MS</last_name>
    <phone>414-937-6833</phone>
    <email>mkarafin@versiti.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sarah Beggi</last_name>
    <phone>414-937-6833</phone>
    <email>sabeggi@versiti.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical College of Wisconsin and Froedtert Hospital</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Matt Karafin, MD,MS</last_name>
      <phone>414-937-6809</phone>
      <email>mkarafin@versiti.org</email>
    </contact>
    <contact_backup>
      <last_name>Sarah Beggi</last_name>
      <phone>414-937-6833</phone>
      <email>sabeggi@versiti.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>July 19, 2019</study_first_submitted>
  <study_first_submitted_qc>July 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2019</study_first_posted>
  <last_update_submitted>May 5, 2020</last_update_submitted>
  <last_update_submitted_qc>May 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Versiti</investigator_affiliation>
    <investigator_full_name>Matthew Karafin</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

